


NF-κB-IN-15

Cat. No.:	HY-162316
Molecular Formula:	C ₄₆ H ₅₈ N ₄ O ₈
Molecular Weight:	794.97
Target:	NF-κB
Pathway:	NF-κB
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	NF-κB-IN-15 (compound 14r) is a potent NF-κB inhibitor. NF-κB-IN-15 decreases the NO levels and inhibits the release of IL-6, TNF-α, and IL-1β in LPS (HY-D1056) -induced cells. NF-κB-IN-15 inhibits LPS-induced phosphorylation of p65 and degradation of IκBα. NF-κB-IN-15 shows anti-inflammatory activity has the potential for the research of acute lung injury (ALI) ^[1] .								
In Vitro	<p>NF-κB-IN-15 (compound 14r) (1.25, 2.5, 5, 10, 20 μM; 1+24 h) decreases the NO levels in a dose-dependent manner and inhibits the release of IL-6, TNF-α, and IL-1β in LPS-induced RAW 264.7 cells^[1].</p> <p>NF-κB-IN-15 (10, 20 μM; 1+4 h) inhibits LPS-induced phosphorylation of p65 and degradation of IκBα^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>RAW 264.7 cells^[1]</td> </tr> <tr> <td>Concentration:</td> <td>10, 20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>1 h (LPS (1 μg/mL) for 4 h)</td> </tr> <tr> <td>Result:</td> <td>Decreased the expression of p-p65 and inhibited degradation of IκBα. LPS-induced levels of IL-6, TNF-α, and IL-1β.</td> </tr> </table>	Cell Line:	RAW 264.7 cells ^[1]	Concentration:	10, 20 μM	Incubation Time:	1 h (LPS (1 μg/mL) for 4 h)	Result:	Decreased the expression of p-p65 and inhibited degradation of IκBα. LPS-induced levels of IL-6, TNF-α, and IL-1β.
Cell Line:	RAW 264.7 cells ^[1]								
Concentration:	10, 20 μM								
Incubation Time:	1 h (LPS (1 μg/mL) for 4 h)								
Result:	Decreased the expression of p-p65 and inhibited degradation of IκBα. LPS-induced levels of IL-6, TNF-α, and IL-1β.								
In Vivo	<p>NF-κB-IN-15 (compound 14r) (20 mg/kg; i.p.) shows anti-inflammatory activity in Acute lung injury (ALI) mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>18-20 g, Male C57BL/6 mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>20 mg/kg+LPS (15 mg/kg, i. p.)</td> </tr> <tr> <td>Administration:</td> <td>i.p.</td> </tr> <tr> <td>Result:</td> <td>Reduced the LPS-induced levels of IL-6, TNF-α, and IL-1β in the bronchoalveolar lavage fluid (BALF) and acute lung injury.</td> </tr> </table>	Animal Model:	18-20 g, Male C57BL/6 mice ^[1]	Dosage:	20 mg/kg+LPS (15 mg/kg, i. p.)	Administration:	i.p.	Result:	Reduced the LPS-induced levels of IL-6, TNF-α, and IL-1β in the bronchoalveolar lavage fluid (BALF) and acute lung injury.
Animal Model:	18-20 g, Male C57BL/6 mice ^[1]								
Dosage:	20 mg/kg+LPS (15 mg/kg, i. p.)								
Administration:	i.p.								
Result:	Reduced the LPS-induced levels of IL-6, TNF-α, and IL-1β in the bronchoalveolar lavage fluid (BALF) and acute lung injury.								

REFERENCES

[1]. Zhang J, et al. Total synthesis and structural modification of the dibenzylbutane lignan LCA as a potent anti-inflammatory agent against LPS-induced acute lung injury. Eur J Med Chem. 2024 Feb 20;268:116272.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA